Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

Milena Braga-Basaria, Adrian S Dobs, Denis C. Muller, Michael A Carducci, Majnu John, Josephine Egan, Shehzad Basaria

Research output: Contribution to journalArticle

Abstract

Purpose: Prostate cancer (PCa) is one of the most common cancers in men. Men with recurrent or metastatic PCa are treated with androgen-deprivation therapy (ADT), resulting in profound hypogonadism. Because male hypogonadism is a risk factor for metabolic syndrome and men with PCa have high cardiovascular mortality, we evaluated the prevalence of metabolic syndrome in men undergoing long-term ADT. Patients and Methods: This was a cross-sectional study. We evaluated 58 men, including 20 with PCa undergoing ADT for at least 12 months (ADT group), 18 age-matched men with nonmetastatic PCa who had received local treatment and were recently found to have an increasing prostate-specific antigen (non-ADT group), and 20 age-matched controls (control group). Men in the non-ADT and control groups were eugonadal. Metabolic syndrome was defined according to the Adult Treatment Panel III criteria. Results: Mean age was similar among the groups. Men on ADT had significantly higher body mass index and lower total and free testosterone levels. The prevalence of metabolic syndrome was higher in the ADT group compared with the non-ADT (P <.01) and control (P = .03) groups. Among the components of metabolic syndrome, men on ADT had a higher prevalence of abdominal obesity and hyperglycemia. Androgen-deprived men also had elevated triglycerides compared with controls (P = .02). The prevalence of hypertension and low high-density lipoprotein levels were similar. Conclusion: These data suggest that metabolic syndrome was present in more than 50% of the men undergoing long-term ADT, predisposing them to higher cardiovascular risk. Abdominal obesity and hyperglycemia were responsible for this higher prevalence. We recommend prospective studies to further delineate this association.

Original languageEnglish (US)
Pages (from-to)3979-3983
Number of pages5
JournalJournal of Clinical Oncology
Volume24
Issue number24
DOIs
StatePublished - Aug 20 2006

Fingerprint

Androgens
Prostatic Neoplasms
Group Psychotherapy
Therapeutics
Abdominal Obesity
Hyperglycemia
Age Groups
Eunuchism
Control Groups
Hypogonadism
HDL Lipoproteins
Prostate-Specific Antigen
LDL Lipoproteins
Testosterone
Triglycerides
Body Mass Index
Cross-Sectional Studies
Prospective Studies
Hypertension
Mortality

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. / Braga-Basaria, Milena; Dobs, Adrian S; Muller, Denis C.; Carducci, Michael A; John, Majnu; Egan, Josephine; Basaria, Shehzad.

In: Journal of Clinical Oncology, Vol. 24, No. 24, 20.08.2006, p. 3979-3983.

Research output: Contribution to journalArticle

Braga-Basaria, Milena ; Dobs, Adrian S ; Muller, Denis C. ; Carducci, Michael A ; John, Majnu ; Egan, Josephine ; Basaria, Shehzad. / Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 24. pp. 3979-3983.
@article{21138531de774c3ab0ab20a4a43907e6,
title = "Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy",
abstract = "Purpose: Prostate cancer (PCa) is one of the most common cancers in men. Men with recurrent or metastatic PCa are treated with androgen-deprivation therapy (ADT), resulting in profound hypogonadism. Because male hypogonadism is a risk factor for metabolic syndrome and men with PCa have high cardiovascular mortality, we evaluated the prevalence of metabolic syndrome in men undergoing long-term ADT. Patients and Methods: This was a cross-sectional study. We evaluated 58 men, including 20 with PCa undergoing ADT for at least 12 months (ADT group), 18 age-matched men with nonmetastatic PCa who had received local treatment and were recently found to have an increasing prostate-specific antigen (non-ADT group), and 20 age-matched controls (control group). Men in the non-ADT and control groups were eugonadal. Metabolic syndrome was defined according to the Adult Treatment Panel III criteria. Results: Mean age was similar among the groups. Men on ADT had significantly higher body mass index and lower total and free testosterone levels. The prevalence of metabolic syndrome was higher in the ADT group compared with the non-ADT (P <.01) and control (P = .03) groups. Among the components of metabolic syndrome, men on ADT had a higher prevalence of abdominal obesity and hyperglycemia. Androgen-deprived men also had elevated triglycerides compared with controls (P = .02). The prevalence of hypertension and low high-density lipoprotein levels were similar. Conclusion: These data suggest that metabolic syndrome was present in more than 50{\%} of the men undergoing long-term ADT, predisposing them to higher cardiovascular risk. Abdominal obesity and hyperglycemia were responsible for this higher prevalence. We recommend prospective studies to further delineate this association.",
author = "Milena Braga-Basaria and Dobs, {Adrian S} and Muller, {Denis C.} and Carducci, {Michael A} and Majnu John and Josephine Egan and Shehzad Basaria",
year = "2006",
month = "8",
day = "20",
doi = "10.1200/JCO.2006.05.9741",
language = "English (US)",
volume = "24",
pages = "3979--3983",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "24",

}

TY - JOUR

T1 - Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

AU - Braga-Basaria, Milena

AU - Dobs, Adrian S

AU - Muller, Denis C.

AU - Carducci, Michael A

AU - John, Majnu

AU - Egan, Josephine

AU - Basaria, Shehzad

PY - 2006/8/20

Y1 - 2006/8/20

N2 - Purpose: Prostate cancer (PCa) is one of the most common cancers in men. Men with recurrent or metastatic PCa are treated with androgen-deprivation therapy (ADT), resulting in profound hypogonadism. Because male hypogonadism is a risk factor for metabolic syndrome and men with PCa have high cardiovascular mortality, we evaluated the prevalence of metabolic syndrome in men undergoing long-term ADT. Patients and Methods: This was a cross-sectional study. We evaluated 58 men, including 20 with PCa undergoing ADT for at least 12 months (ADT group), 18 age-matched men with nonmetastatic PCa who had received local treatment and were recently found to have an increasing prostate-specific antigen (non-ADT group), and 20 age-matched controls (control group). Men in the non-ADT and control groups were eugonadal. Metabolic syndrome was defined according to the Adult Treatment Panel III criteria. Results: Mean age was similar among the groups. Men on ADT had significantly higher body mass index and lower total and free testosterone levels. The prevalence of metabolic syndrome was higher in the ADT group compared with the non-ADT (P <.01) and control (P = .03) groups. Among the components of metabolic syndrome, men on ADT had a higher prevalence of abdominal obesity and hyperglycemia. Androgen-deprived men also had elevated triglycerides compared with controls (P = .02). The prevalence of hypertension and low high-density lipoprotein levels were similar. Conclusion: These data suggest that metabolic syndrome was present in more than 50% of the men undergoing long-term ADT, predisposing them to higher cardiovascular risk. Abdominal obesity and hyperglycemia were responsible for this higher prevalence. We recommend prospective studies to further delineate this association.

AB - Purpose: Prostate cancer (PCa) is one of the most common cancers in men. Men with recurrent or metastatic PCa are treated with androgen-deprivation therapy (ADT), resulting in profound hypogonadism. Because male hypogonadism is a risk factor for metabolic syndrome and men with PCa have high cardiovascular mortality, we evaluated the prevalence of metabolic syndrome in men undergoing long-term ADT. Patients and Methods: This was a cross-sectional study. We evaluated 58 men, including 20 with PCa undergoing ADT for at least 12 months (ADT group), 18 age-matched men with nonmetastatic PCa who had received local treatment and were recently found to have an increasing prostate-specific antigen (non-ADT group), and 20 age-matched controls (control group). Men in the non-ADT and control groups were eugonadal. Metabolic syndrome was defined according to the Adult Treatment Panel III criteria. Results: Mean age was similar among the groups. Men on ADT had significantly higher body mass index and lower total and free testosterone levels. The prevalence of metabolic syndrome was higher in the ADT group compared with the non-ADT (P <.01) and control (P = .03) groups. Among the components of metabolic syndrome, men on ADT had a higher prevalence of abdominal obesity and hyperglycemia. Androgen-deprived men also had elevated triglycerides compared with controls (P = .02). The prevalence of hypertension and low high-density lipoprotein levels were similar. Conclusion: These data suggest that metabolic syndrome was present in more than 50% of the men undergoing long-term ADT, predisposing them to higher cardiovascular risk. Abdominal obesity and hyperglycemia were responsible for this higher prevalence. We recommend prospective studies to further delineate this association.

UR - http://www.scopus.com/inward/record.url?scp=33748474608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748474608&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.05.9741

DO - 10.1200/JCO.2006.05.9741

M3 - Article

VL - 24

SP - 3979

EP - 3983

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 24

ER -